These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27244813)

  • 21. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
    Frampton JE; Keam SJ
    Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Murphy TV; Slade BA; Broder KR; Kretsinger K; Tiwari T; Joyce PM; Iskander JK; Brown K; Moran JS;
    MMWR Recomm Rep; 2008 May; 57(RR-4):1-51. PubMed ID: 18509304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
    Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
    Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
    Gaillard ME; Bottero D; Errea A; Ormazábal M; Zurita ME; Moreno G; Rumbo M; Castuma C; Bartel E; Flores D; van der Ley P; van der Ark A; F Hozbor D
    Vaccine; 2014 Feb; 32(8):931-7. PubMed ID: 24397896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
    Patel SS; Wagstaff AJ
    Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
    Kang KR; Huh DH; Kim JA; Kang JH
    BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare Detection of Bordetella pertussis Pertactin-Deficient Strains in Argentina.
    Carriquiriborde F; Regidor V; Aispuro PM; Magali G; Bartel E; Bottero D; Hozbor D
    Emerg Infect Dis; 2019 Nov; 25(11):2048-2054. PubMed ID: 31625838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why do pertussis vaccines fail?
    Cherry JD
    Pediatrics; 2012 May; 129(5):968-70. PubMed ID: 22529282
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis.
    Baxter R; Bartlett J; Fireman B; Lewis E; Klein NP
    Pediatrics; 2017 May; 139(5):. PubMed ID: 28557752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
    Hegerle N; Dore G; Guiso N
    Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
    Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
    Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration of protection after first dose of acellular pertussis vaccine in infants.
    Quinn HE; Snelling TL; Macartney KK; McIntyre PB
    Pediatrics; 2014 Mar; 133(3):e513-9. PubMed ID: 24515514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
    Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
    JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin.
    Hijnen M; He Q; Schepp R; Van Gageldonk P; Mertsola J; Mooi FR; Berbers GA
    Scand J Infect Dis; 2008; 40(2):94-104. PubMed ID: 17926203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.